CY1110170T1 - Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης - Google Patents

Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης

Info

Publication number
CY1110170T1
CY1110170T1 CY20101100506T CY101100506T CY1110170T1 CY 1110170 T1 CY1110170 T1 CY 1110170T1 CY 20101100506 T CY20101100506 T CY 20101100506T CY 101100506 T CY101100506 T CY 101100506T CY 1110170 T1 CY1110170 T1 CY 1110170T1
Authority
CY
Cyprus
Prior art keywords
pyrrolidinone
phenyl
carbamoylmethyl
preparation
pharmaceutical use
Prior art date
Application number
CY20101100506T
Other languages
English (en)
Inventor
Grigory Veinberg
Maksim Vorona
Liga Zvejniece
Aleksandrs Chernobrovijs
Ivars Kalvinsh
Ligita Karina
Maija Dambrova
Original Assignee
Akciju Sabiedriba "Olainfarm"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akciju Sabiedriba "Olainfarm" filed Critical Akciju Sabiedriba "Olainfarm"
Publication of CY1110170T1 publication Critical patent/CY1110170T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η εφεύρεση αφορά το R-εναντιομερές Ν-καρβαμοϋλμεθυλ-4-φαινυλ-2-πυρρολιδόνης (R Carphedon) φαρμακολογικής αξίας. Η μέθοδος παρασκευής αυτού περιλαμβάνει την Ν-αλκυλίωση 4(R)-φαινυλ-2-πυρρολιδόνης με βρωμοοξεικό αιθυλεστέρα παρουσία ισχυρής βάσης και την κατεργασία ενδιάμεσης Ν-αιθοξυκαρβονυλμεθυλ-4(R)-φαινυλ-2-πυρρολιδόνης με αμμωνία.
CY20101100506T 2006-03-16 2010-06-08 Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης CY1110170T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
EP07726915A EP2013166B1 (en) 2006-03-16 2007-03-15 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use

Publications (1)

Publication Number Publication Date
CY1110170T1 true CY1110170T1 (el) 2015-01-14

Family

ID=38461010

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100506T CY1110170T1 (el) 2006-03-16 2010-06-08 Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης

Country Status (21)

Country Link
US (2) US9102615B2 (el)
EP (1) EP2013166B1 (el)
CN (1) CN101448786A (el)
AT (1) ATE460396T1 (el)
CA (1) CA2647206C (el)
CY (1) CY1110170T1 (el)
DE (1) DE602007005244D1 (el)
DK (1) DK2013166T3 (el)
EA (1) EA014668B1 (el)
EE (1) EE05536B1 (el)
ES (1) ES2342024T3 (el)
GE (1) GEP20104915B (el)
HR (1) HRP20090524C1 (el)
LT (1) LT5589B (el)
LV (1) LV13630B (el)
ME (1) ME01192B (el)
PL (1) PL2013166T3 (el)
PT (1) PT2013166E (el)
SI (1) SI2013166T1 (el)
UA (1) UA96440C2 (el)
WO (1) WO2007104780A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
EP2694474A1 (en) * 2011-03-11 2014-02-12 Grindeks 4r,5r-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
EP3741772B1 (en) 2012-05-08 2024-06-19 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
TW201408293A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
LV15015B (lv) 2013-12-13 2015-12-20 Olainfarm, A/S 3-karboksi-4-(R)-fenilpirolidin-2-ona sāls un tā pielietošana
LV15016B (lv) 2013-12-18 2016-01-20 Olainfarm, A/S N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas
EP2891491A1 (en) 2014-01-03 2015-07-08 Merz Pharma GmbH & Co. KGaA Use of (r)-phenylpiracetam for the treatment of sleep disorders
LV15072B (lv) 2014-05-14 2016-09-20 Olainfarm, A/S Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
EP3127539A1 (en) 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2289404C1 (ru) * 2005-04-06 2006-12-20 ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах

Also Published As

Publication number Publication date
EA200801978A1 (ru) 2009-04-28
US9382203B2 (en) 2016-07-05
WO2007104780A3 (en) 2007-11-29
SI2013166T1 (sl) 2010-07-30
DE602007005244D1 (de) 2010-04-22
UA96440C2 (ru) 2011-11-10
CA2647206C (en) 2011-09-27
LT5589B (lt) 2009-08-25
US20100022784A1 (en) 2010-01-28
LV13630B (en) 2007-12-20
LT2008075A (en) 2009-06-25
HRPK20090524B3 (hr) 2012-12-31
EE05536B1 (et) 2012-04-16
HRP20090524C1 (hr) 2017-03-10
US20150216846A1 (en) 2015-08-06
ES2342024T3 (es) 2010-06-30
HRP20090524A2 (hr) 2009-12-31
PT2013166E (pt) 2010-06-09
DK2013166T3 (da) 2010-07-05
EE200800063A (et) 2008-12-15
CA2647206A1 (en) 2007-09-20
PL2013166T3 (pl) 2010-08-31
GEP20104915B (en) 2010-03-10
ATE460396T1 (de) 2010-03-15
CN101448786A (zh) 2009-06-03
ME01192B (me) 2012-12-20
WO2007104780A2 (en) 2007-09-20
EP2013166A2 (en) 2009-01-14
US9102615B2 (en) 2015-08-11
EP2013166B1 (en) 2010-03-10
EA014668B1 (ru) 2010-12-30

Similar Documents

Publication Publication Date Title
CY1110170T1 (el) Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
DE602005003478D1 (de) Mit umfaltreitern versehene zettel und fahnen
FR2910473B1 (fr) Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
CR20110042A (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo [1,4]dioxin-2-ilmetil)-sulfamida
DE50305369D1 (de) Hochdruck-sensor mit silizium-membran und lotschicht
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
FR2904316B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
ATE553082T1 (de) 5,6-bisaryl-2-pyridin-carboxamid-derivate sowie ihre herstellung und anwendung in therapeutika als urotensin-ii-rezeptor-antagonisten
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
FR2886852B1 (fr) Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee